Stock message boards
MNV
Market News Video
MNV MNV Model Portfolios ChartZero
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

PFE May 9th Options Begin Trading
Thursday, March 27, 11:24 AM ET, by Market News Video Staff

Investors in Pfizer Inc (PFE) saw new options begin trading today, for the May 9th ...

Ex-Dividend Reminder: Bristol-Myers Squibb, DCT Industrial Trust Inc and Aviva plc
Monday, March 31, 10:12 AM ET, by Market News Video Staff

On 4/2/14, Bristol-Myers Squibb Co. (BMY), DCT Industrial Trust Inc (DCT), and Aviva plc (AV) ...

Interesting January 2016 Stock Options for PFE
Monday, March 31, 12:13 PM ET, by Market News Video Staff

Consistently, one of the more popular stocks people enter into their stock options watchlist at ...

Noteworthy ETF Outflows: IVW, UPS, CELG, BMY
Wednesday, April 2, 10:58 AM ET, by Market News Video Staff

Symbols mentioned in this story: IVW, UPS, CELG, BMY Exchange traded funds (ETFs) trade just ...

Notable ETF Inflow Detected - VTV, JPM, PFE, T
Wednesday, April 2, 10:59 AM ET, by Market News Video Staff

Symbols mentioned in this story: VTV, JPM, PFE, T Exchange traded funds (ETFs) trade just ...

  More articles:  1 2 3 4 5 6 7 next »

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer

By Market News Video Staff, Monday, August 29, 8:47 AM ET
Play Video: The Importance of ETFs


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) announced over the weekend positive results in a Phase 3 trial that compared Elquis to warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation and at least one risk factor for stroke.

The companies said the drug showed Elquis significantly reduced the risk of stroke or systemic embolism by 21%, major bleeding by 31%, and mortality by 11%. Separately, Pfizer said that the Food and Drug Administration has approved Xalkori capsules, which the company calls the first-ever drug targeting anaplastic lymphoma kinase, or ALK, for the treatment of locally advanced or metastatic non-small cell lung cancer that is ALK-positive.

Pfizer noted that lung cancer is responsible for more deaths each years worldwide than any other type of cancer, and the drug offers a new treatment option for a subset of patients with the disease.

The FDA gave the drug accelerated approval, and Pfizer is conducting post-marketing clinical trials to further evaluate its clinical benefit. Pfizer partnered with Abbott Laboratories’ (NYSE:ABT) Molecular business on a diagnostic test for ALK, which was approved simultaneously with the drug. Xalkori is available immediately through some pharmacies.


Top Six Most Viewed Stories This Week @ Market News Video:
Thursday 4/17 Insider Buying Report: SHLD, OPKThursday 4/17 Insider Buying Report: SHLD, OPK
Channel: Insider Buying Report
Related symbols: SHLD,OPK
Nasdaq 100 Movers: GOOGL, SNDKNasdaq 100 Movers: GOOGL, SNDK
Channel: Large Cap Stocks
Related symbols: GOOGL,SNDK
Thursday Sector Laggards: Music & Electronics Stores, General Contractors & BuildersThursday Sector Laggards: Music & Electronics Stores, General Contractors & Builders
Channel: Market Movers
Related symbols: RSH,CONN,HXM,MHO
Dow Movers: UNH, GEDow Movers: UNH, GE
Channel: Large Cap Stocks
Related symbols: UNH,GE
Thursday Sector Leaders: Communications Services, Agriculture & Farm ProductsThursday Sector Leaders: Communications Services, Agriculture & Farm Products
Channel: Market Movers
Related symbols: ETAK,CRCM,GRO,CRESY
Thursday 4/17 Insider Buying Report: RTThursday 4/17 Insider Buying Report: RT
Channel: Insider Buying Report
Related symbols: RT

This Article's Word Cloud:   Abbott   Administration   Definition   Definitions   Drug   Earnings   Elquis   Food   Myers   NYSE   Pfizer   Quadruple   Rate   Relevant   Squibb   Xalkori   approved   atrial   benefit   business   calls   cancer   cell   clinical   companies   company   conducting   disease   drug   embolism   factor   lung   marketing   option   patients   positive   prevention   responsible   risk   said   stroke   systemic   test   that   treatment   trials   weekend   which   with   years
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use & Privacy Policy - Video Widget
MNV
Home  |  Analyst News  Dividend Report  Econonomic News  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Stock Market Definitions
MNV

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer | Market News Video | Copyright © 2008 - 2014, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.